Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system

Anthony B. Nesburn, Ilham Bettahi, Xiuli Zhang, Xiaoming Zhu, Winston Chamberlain, Rasha E. Afifi, Steven L. Wechsler, Lbachir Benmohamed

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although ocular mucosal immunity is highly beneficial for achieving protective immunity, the induction of ocular mucosal immunity against ocular infectious pathogens, particularly herpes simplex virus type 1 (HSV-1), which is the leading cause of infectious corneal blindness, remains difficult. Recent developments in cellular and molecular immunology of the ocular mucosal immune system (OMIS) may help in the design of more effective and optimal immunization strategies against ocular pathogens. In this review, we highlight ocular mucosal immunoprophylactic and immunotherapeutic vaccine strategies that have been evaluated to control the many pathogens that attack the surface of the eye. Next, we describe the current understandings of the OMIS and elucidate the structure and the function of the humoral and cellular immune system that protects the surface of the eye. Results from our recent experiments using topical ocular delivery of peptides-CpG and lipopeptide-based vaccines against HSV-1 infection are presented. The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed.

Original languageEnglish (US)
Pages (from-to)178-187
Number of pages10
JournalOcular Surface
Volume4
Issue number4
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Immune System
Vaccines
Mucosal Immunity
Human Herpesvirus 1
Lipopeptides
Virus Diseases
Blindness
Allergy and Immunology
Immunity
Immunization
Vaccination
Peptides

Keywords

  • Conjunctiva-associated lymphoid tissue (CALT)
  • Epitope
  • Eye-associated lymphoid tissue (EALT)
  • Herpes virus
  • Immune response
  • Lipopeptide
  • Mucosa-associated lymphoid tissue (MALT)
  • Mucosal immune system
  • Ocular mucosal immune system (OMIS)
  • Vaccine

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Nesburn, A. B., Bettahi, I., Zhang, X., Zhu, X., Chamberlain, W., Afifi, R. E., ... Benmohamed, L. (2006). Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocular Surface, 4(4), 178-187.

Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. / Nesburn, Anthony B.; Bettahi, Ilham; Zhang, Xiuli; Zhu, Xiaoming; Chamberlain, Winston; Afifi, Rasha E.; Wechsler, Steven L.; Benmohamed, Lbachir.

In: Ocular Surface, Vol. 4, No. 4, 10.2006, p. 178-187.

Research output: Contribution to journalArticle

Nesburn, AB, Bettahi, I, Zhang, X, Zhu, X, Chamberlain, W, Afifi, RE, Wechsler, SL & Benmohamed, L 2006, 'Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system', Ocular Surface, vol. 4, no. 4, pp. 178-187.
Nesburn, Anthony B. ; Bettahi, Ilham ; Zhang, Xiuli ; Zhu, Xiaoming ; Chamberlain, Winston ; Afifi, Rasha E. ; Wechsler, Steven L. ; Benmohamed, Lbachir. / Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. In: Ocular Surface. 2006 ; Vol. 4, No. 4. pp. 178-187.
@article{62f4a4fc7e60496dbade3d7577dfc1db,
title = "Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system",
abstract = "Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although ocular mucosal immunity is highly beneficial for achieving protective immunity, the induction of ocular mucosal immunity against ocular infectious pathogens, particularly herpes simplex virus type 1 (HSV-1), which is the leading cause of infectious corneal blindness, remains difficult. Recent developments in cellular and molecular immunology of the ocular mucosal immune system (OMIS) may help in the design of more effective and optimal immunization strategies against ocular pathogens. In this review, we highlight ocular mucosal immunoprophylactic and immunotherapeutic vaccine strategies that have been evaluated to control the many pathogens that attack the surface of the eye. Next, we describe the current understandings of the OMIS and elucidate the structure and the function of the humoral and cellular immune system that protects the surface of the eye. Results from our recent experiments using topical ocular delivery of peptides-CpG and lipopeptide-based vaccines against HSV-1 infection are presented. The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed.",
keywords = "Conjunctiva-associated lymphoid tissue (CALT), Epitope, Eye-associated lymphoid tissue (EALT), Herpes virus, Immune response, Lipopeptide, Mucosa-associated lymphoid tissue (MALT), Mucosal immune system, Ocular mucosal immune system (OMIS), Vaccine",
author = "Nesburn, {Anthony B.} and Ilham Bettahi and Xiuli Zhang and Xiaoming Zhu and Winston Chamberlain and Afifi, {Rasha E.} and Wechsler, {Steven L.} and Lbachir Benmohamed",
year = "2006",
month = "10",
language = "English (US)",
volume = "4",
pages = "178--187",
journal = "Ocular Surface",
issn = "1542-0124",
publisher = "Ethis Communications, Inc.",
number = "4",

}

TY - JOUR

T1 - Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system

AU - Nesburn, Anthony B.

AU - Bettahi, Ilham

AU - Zhang, Xiuli

AU - Zhu, Xiaoming

AU - Chamberlain, Winston

AU - Afifi, Rasha E.

AU - Wechsler, Steven L.

AU - Benmohamed, Lbachir

PY - 2006/10

Y1 - 2006/10

N2 - Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although ocular mucosal immunity is highly beneficial for achieving protective immunity, the induction of ocular mucosal immunity against ocular infectious pathogens, particularly herpes simplex virus type 1 (HSV-1), which is the leading cause of infectious corneal blindness, remains difficult. Recent developments in cellular and molecular immunology of the ocular mucosal immune system (OMIS) may help in the design of more effective and optimal immunization strategies against ocular pathogens. In this review, we highlight ocular mucosal immunoprophylactic and immunotherapeutic vaccine strategies that have been evaluated to control the many pathogens that attack the surface of the eye. Next, we describe the current understandings of the OMIS and elucidate the structure and the function of the humoral and cellular immune system that protects the surface of the eye. Results from our recent experiments using topical ocular delivery of peptides-CpG and lipopeptide-based vaccines against HSV-1 infection are presented. The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed.

AB - Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although ocular mucosal immunity is highly beneficial for achieving protective immunity, the induction of ocular mucosal immunity against ocular infectious pathogens, particularly herpes simplex virus type 1 (HSV-1), which is the leading cause of infectious corneal blindness, remains difficult. Recent developments in cellular and molecular immunology of the ocular mucosal immune system (OMIS) may help in the design of more effective and optimal immunization strategies against ocular pathogens. In this review, we highlight ocular mucosal immunoprophylactic and immunotherapeutic vaccine strategies that have been evaluated to control the many pathogens that attack the surface of the eye. Next, we describe the current understandings of the OMIS and elucidate the structure and the function of the humoral and cellular immune system that protects the surface of the eye. Results from our recent experiments using topical ocular delivery of peptides-CpG and lipopeptide-based vaccines against HSV-1 infection are presented. The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed.

KW - Conjunctiva-associated lymphoid tissue (CALT)

KW - Epitope

KW - Eye-associated lymphoid tissue (EALT)

KW - Herpes virus

KW - Immune response

KW - Lipopeptide

KW - Mucosa-associated lymphoid tissue (MALT)

KW - Mucosal immune system

KW - Ocular mucosal immune system (OMIS)

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=34447293406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447293406&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 178

EP - 187

JO - Ocular Surface

JF - Ocular Surface

SN - 1542-0124

IS - 4

ER -